INM (InMed Pharmaceuticals) Interest Expense: $-0.02 Mil (TTM As of Mar. 2026)

What is InMed Pharmaceuticals Interest Expense?

InMed Pharmaceuticals INM -0.61% 29 Interest Expense is $-0.02 Mil as of Mar. 2026. GuruFocus rates INM with a GF Score™ of 29/100 and a GF Value™ of $0.93 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. InMed Pharmaceuticals's interest expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. InMed Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was $ -2.82 Mil. InMed Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was $ 0.00 Mil. GuruFocus does not calculate InMed Pharmaceuticals's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InMed Pharmaceuticals (NAS:INM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InMed Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-2.82 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.03 Mil.

InMed Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate InMed Pharmaceuticals's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

InMed Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's Interest Expense can be seen below:

InMed Pharmaceuticals Interest Expense Chart

InMed Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Interest Expense

Get a 7-Day Free Trial

-0.36

0.00

-0.37

InMed Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															0.00	-0.02	0.00	0.00	0.00

29GF Score

InMed Pharmaceuticals Inc INM

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

InMed Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-0.02 Mil mean?

InMed Pharmaceuticals (INM) has a Interest Expense of $-0.02 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on InMed Pharmaceuticals and its competitors.

Is InMed Pharmaceuticals' Interest Expense too high?

InMed Pharmaceuticals' current Interest Expense is $-0.02 Mil. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does InMed Pharmaceuticals' Interest Expense compare to SNOA and CVSI?

InMed Pharmaceuticals' Interest Expense of $-0.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Drug Manufacturers company?

A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on InMed Pharmaceuticals and its competitors. InMed Pharmaceuticals's current Interest Expense is $-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is InMed Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, InMed Pharmaceuticals (INM) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.93, compared to a current price of $1.65 — trading 77.4% above its estimated fair value. The current Interest Expense is $-0.02 Mil. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current Interest Expense is $-0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InMed Pharmaceuticals (INM) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of $1.65 is trading 77.4% above its estimated GF Value™ of $0.93. GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INM:

Interest Expense: $-0.02 Mil
GF Value™: $0.93 vs. price of $1.65 (77.4% above fair value)
GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the INM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InMed Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies SNOA CVSI PRFX SBFM CTTH BUDZ LVRLF GELS YCBD CBIH XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges MWG:Germany

Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8

Website https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.

29GF Score

Get the complete analysis for INM

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65

Price

$0.93

GF Value

View INM Analysis

See Interest Expense data for all stocks →